NCT01124630已完成1 期
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
Treatment with CS-1008 in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil [5-FU]) in subjects with metastatic colorectal cancer (CRC) who have failed first-line treatment that was not irinotecan-based.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed, metastatic CRC that has progressed after first-line standard therapy that was not irinotecan-based.
- •At least 18 years of age.
- •Eastern Cooperative Oncology Group (ECOG) performance status of =<
- •Adequate organ and bone marrow function as evidenced by:
- •Hemoglobin >= 9 g/dL
- •White blood cell count (WBC) >= 3.0 x 109/L
- •Absolute neutrophil count (ANC) >= 1.5 x 109/L
- •Platelet count >= 100 x 109/L
- •Serum creatinine < the upper limit of normal (ULN)
- •AST and alkaline phosphatase =< 2.5 x ULN if without liver metastasis and =< 5.0 x ULN if liver metastasis
- •Total bilirubin =< ULN
- •Male and female subjects of reproductive potential must be willing to consent to using effective contraception while on treatment and for 3 months after the end of treatment.
- •Female subjects of childbearing potential must have a negative pregnancy test (serum or urine) result within 8 days before starting study treatment.
- •Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IRB-approved ICF before performance of any study-specific procedures or tests.
- •At study centers located in the US, subjects must also sign a HIPAA authorization.
- •KRAS Mutant
排除标准
- •Anticipation of a need for a major surgical procedure or radiotherapy (RT) during the study.
- •Treatment with chemotherapy, hormonal therapy, RT, minor surgery, or any investigational agent within 4 weeks before study enrollment. Treatment with nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery within 6 weeks before study enrollment.
- •First-line therapy for CRC that was irinotecan-based.
- •History of any of the following conditions within 6 months before study enrollment:
- •Myocardial infarction;
- •Severe/unstable angina pectoris;
- •Coronary/peripheral artery bypass graft;
- •New York Heart Association (NYHA) class III or IV congestive heart failure;
- •Cerebrovascular accident or transient ischemic attack;
- •Pulmonary embolism or other clinically significant thromboembolic event; or
- •Clinically significant pulmonary disease (eg, severe chronic obstructive pulmonary disease or asthma).
- •Clinically active brain metastasis (ie, untreated, still requiring therapy with steroids or RT, or with progression within 4 weeks after completion of RT); an uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.
- •History of malignancy other than CRC, unless there is the expectation that the malignancy has been cured, and tumor-specific treatment for the malignancy has not been administered within the previous 5 years.
- •Clinically significant active infection that requires antibiotic therapy or Human Immunodeficiency Virus (HIV)-positive subjects receiving antiretroviral therapy.
- •Previous treatment with CS-1008, other agonistic DRSantibodies, or with TRAIL agonists.
- •If female, pregnant or breastfeeding.
- •Known history of hypersensitivity reactions to any of the components of CS-1008, irinotecan, leucovorin, or 5-FU formulations.
- •Serious intercurrent medical or psychiatric illnesses or any other conditions that in the opinion of the Investigator would impair the ability to give informed consent or unacceptably reduce protocol compliance or safety of the study treatment.
- •Must not be known to be homozygous for the UGT1A1*28 allele, as this increases the risk for neutropenia following irinotecan treatment.
- •Kras allele status must not be wild type.
- •Dihydropyrimidine dehydrogenase (DPD) deficiency.
研究组 & 干预措施
CS-1008 with FOLFIRI
Experimental
Experimental drug CS-1008 in combination with FOLFIRI
干预措施: CS-1008 (Drug)
CS-1008 with FOLFIRI
Experimental
Experimental drug CS-1008 in combination with FOLFIRI
干预措施: FOLFIRI (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: up to 6 months
To obtain a preliminary assessment of the antitumor activity of CS-1008 in combination with a FOLFIRI regimen based on the Objective Response Rate (ORR)
Progression Free Survival
时间窗: up to 6 months
To obtain a preliminary assessment of the antitumor activity of CS-1008 in combination with a FOLFIRI regimen based on the Progression Free Survival (PFS)
次要结局
- Serum concentrations(weekly)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver CancerAdvanced Hepatocellular CarcinomaHepatic CancerLiver NeoplasmsLiver CancerNCT01033240Daiichi Sankyo172
招募中
2 期
PhaseII study of Combination FOLFIRI with Cetuximab in patients with advanced/metastatic colorectal cancer previously received oxaliplatin-based chemoterapy.Colorectal CancerJPRN-UMIN000007372Kurume University School of medicine, Department of Surgery30
已完成
3 期
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT00457691Pfizer768
Unknown
3 期
FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer PatientsColorectal CarcinomaNCT02935764Fudan University164
终止
2 期
CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With OxaliplatinMetastatic Colorectal CancerNCT00969033Daiichi Sankyo8